2026 Global: Biodegradable Stents Market -Competitive Review (2032) report
Description
The 2026 Global: Biodegradable Stents Market -Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for biodegradable stents market by geography and historical trend. The scope of the report extends to sizing of the biodegradable stents market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Abbott Laboratories, Boston Scientific Corporation, and Biotronik SE & Co. KG lead the biodegradable stents market, alongside Terumo Corporation, Teleflex, Reva Medical, MicroPort Scientific, Kyoto Medical Planning, Elixir Medical, and QualiMed, driving innovation through polymeric and metallic platforms. These ten companies command significant shares amid a market projected to reach USD 441.69 million in 2025, growing at a 7.51% CAGR to USD 634.37 million by 2030, fueled by rising cardiovascular disease prevalence and demand for minimally invasive procedures. Abbott Laboratories pioneered bioresorbable scaffolds like Absorb, leveraging extensive clinical data on poly-L-lactic acid (PLLA) technology, which held 61.22% market share in 2024 for its alignment with vessel healing timelines. Boston Scientific advances limus-based coatings, capturing revenue through everolimus-eluting platforms that match scaffold resorption, while maintaining dominance in hospital procedures accounting for 67.45% of deployments. Biotronik SE & Co. KG excels in magnesium-based stents like Freesolve, resorbed within 12-18 months, bolstered by Teleflex's February 2025 acquisition of its vascular intervention arm to expand global reach.
Terumo Corporation and Reva Medical focus on next-generation alloys, with MicroPort Scientific securing NMPA approval for Firesorb in July 2024, enhancing Asia-Pacific growth at a 10.12% CAGR through localized production in China and India. Terumo integrates polymeric scaffolds into its interventional portfolio, targeting multivessel disease with strong radial strength from advanced metallurgy closing gaps with drug-eluting stents (DES). Reva Medical specializes in proprietary biomaterials, emphasizing full bioresorption to eliminate lifelong antiplatelet therapy needs, appealing to high-risk patients via established sales channels. MicroPort's Firesorb represents polymeric innovation, dissolving post-deployment to minimize vascular injury over permanent metal alternatives, supported by government investments in cardiology training. Teleflex strengthens its position via strategic buys, adding magnesium platforms to leverage manufacturing scale and cost efficiencies in fragmented markets undergoing consolidation.
Kyoto Medical Planning, Elixir Medical, and QualiMed innovate in bioabsorbable polymers, addressing regulatory hurdles while North America leads adoption due to sophisticated infrastructure. Kyoto Medical develops PLLA-based scaffolds for precise artery restoration, contributing to market forecasts of USD 779.3 million by 2032 at 7.4% CAGR. Elixir Medical advances hybrid architectures for mid-term healing, partnering on trials to validate long-term benefits amid R&D focusing on global approvals. QualiMed and peers like ENDOCOR GmbH target emerging regions, where obesity and smoking drive demand, with bioresorbable vascular scaffolds projected at 5.19% CAGR to USD 639.32 million by 2032. These firms navigate commercialization challenges through patent strategies and clinical evidence, positioning biodegradable stents to displace metallic DES via reduced complications and cost-effectiveness.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for biodegradable stents market by geography and historical trend. The scope of the report extends to sizing of the biodegradable stents market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Abbott Laboratories, Boston Scientific Corporation, and Biotronik SE & Co. KG lead the biodegradable stents market, alongside Terumo Corporation, Teleflex, Reva Medical, MicroPort Scientific, Kyoto Medical Planning, Elixir Medical, and QualiMed, driving innovation through polymeric and metallic platforms. These ten companies command significant shares amid a market projected to reach USD 441.69 million in 2025, growing at a 7.51% CAGR to USD 634.37 million by 2030, fueled by rising cardiovascular disease prevalence and demand for minimally invasive procedures. Abbott Laboratories pioneered bioresorbable scaffolds like Absorb, leveraging extensive clinical data on poly-L-lactic acid (PLLA) technology, which held 61.22% market share in 2024 for its alignment with vessel healing timelines. Boston Scientific advances limus-based coatings, capturing revenue through everolimus-eluting platforms that match scaffold resorption, while maintaining dominance in hospital procedures accounting for 67.45% of deployments. Biotronik SE & Co. KG excels in magnesium-based stents like Freesolve, resorbed within 12-18 months, bolstered by Teleflex's February 2025 acquisition of its vascular intervention arm to expand global reach.
Terumo Corporation and Reva Medical focus on next-generation alloys, with MicroPort Scientific securing NMPA approval for Firesorb in July 2024, enhancing Asia-Pacific growth at a 10.12% CAGR through localized production in China and India. Terumo integrates polymeric scaffolds into its interventional portfolio, targeting multivessel disease with strong radial strength from advanced metallurgy closing gaps with drug-eluting stents (DES). Reva Medical specializes in proprietary biomaterials, emphasizing full bioresorption to eliminate lifelong antiplatelet therapy needs, appealing to high-risk patients via established sales channels. MicroPort's Firesorb represents polymeric innovation, dissolving post-deployment to minimize vascular injury over permanent metal alternatives, supported by government investments in cardiology training. Teleflex strengthens its position via strategic buys, adding magnesium platforms to leverage manufacturing scale and cost efficiencies in fragmented markets undergoing consolidation.
Kyoto Medical Planning, Elixir Medical, and QualiMed innovate in bioabsorbable polymers, addressing regulatory hurdles while North America leads adoption due to sophisticated infrastructure. Kyoto Medical develops PLLA-based scaffolds for precise artery restoration, contributing to market forecasts of USD 779.3 million by 2032 at 7.4% CAGR. Elixir Medical advances hybrid architectures for mid-term healing, partnering on trials to validate long-term benefits amid R&D focusing on global approvals. QualiMed and peers like ENDOCOR GmbH target emerging regions, where obesity and smoking drive demand, with bioresorbable vascular scaffolds projected at 5.19% CAGR to USD 639.32 million by 2032. These firms navigate commercialization challenges through patent strategies and clinical evidence, positioning biodegradable stents to displace metallic DES via reduced complications and cost-effectiveness.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.